Orion published Half-Year Financial Report for January-June 2020 on Friday, 17 July 2020. The report and related presentation material and webcast recording are available here.
Orion Investor Relations have received several questions related to the coronavirus (COVID-19) pandemia and its impacts on Orion. We have listed here answers to some frequently asked questions.
The 2020 Annual General Meeting of Orion was held on Wednesday, 6 May 2020. The decisions and related material are available here.
Responsibility is one incentive when retail investors seek investments. Pharmaceuticals and healthcare is one of the most interesting sectors.
Research and development are Orion's strengths, and the company will continue to invest in them. The target is to increase net sales 1.5-fold by 2025.
The latest Corporate Governance Statement of Orion Corporation is available at the archive of Corporate Governance Statements.
|7/28/2020||Orion’s phase 3 REFALS trial evaluating the efficacy of oral levosimendan in treatment of ALS patients did not reach its pre-specified endpoints|
|7/17/2020||Orion Group Half-Year Financial Report 1-6/2020|
|7/17/2020||Orion Corporation's financial reporting and Annual General Meeting in 2021|
|7/14/2020||191,501 Orion Corporation A shares converted into B shares|
|9/10/2020||Orion is planning to renew its R&D strategy and organisation|
|9/10/2020||New England Journal of Medicine publishes final overall survival data for darolutamide showing treatment significantly extends life in men with non-metastatic prostate cancer|
|6/26/2020||Orion publishes Half-Year Financial Report for January-June 2020 on Friday 17 July 2020|
|6/26/2020||Distribution of Zoetis’ products in Sweden, Denmark and Norway by Orion to end after 2020|
Information about the price development of Orion's A and B shares. Also available a list of analysts covering Orion and the latest consensus estimate.
Orion Corporation has been included in the globally recognised FTSE4Good Index.